In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Focal Therapeutics Inc.

Division of Hologic Inc.
www.focalrx.com

Latest From Focal Therapeutics Inc.

Market Intel: Breast Imaging Market Driven By AI, Technological Innovation

The global market for breast cancer imaging and biopsy technologies is expected to reach $5.8bn by 2022, a CAGR of 5.9%, driven by innovation technologies and machine-learning tools that serve as "second readers" to help radiologists triage images and find cancers. Many radiologists believe that mammography will remain the most widely used screening tool, but that digital breast tomosynthesis will ultimately become the gold standard. Here's a close look at the overall breast imaging and biopsy market, highlighting different modalities and key players, and offering the real-world use perspective from three radiologists at Kaiser Permanente, San Diego.

Commercial Market Intelligence
See All

Company Information

  • Industry
  • Medical Devices
    • Diagnostic Imaging Equipment & Supplies
    • Implantable Devices
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Hologic Inc.
  • Senior Management
  • John Papandrea, CEO
    Kevin Cousins, CFO
    George Hermann, Pres.
    Dan Beney, VP, Sales
    Gail Lebovic, MD, CMO
  • Contact Info
  • Focal Therapeutics Inc.
    Phone: (855) 764-7528
    30 Enterprise
    Ste. 220
    Aliso Viejo, CA 92656
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register